MARKET

CRMD

CRMD

Cormedix
NASDAQ
4.780
-0.130
-2.65%
After Hours: 4.850 +0.07 +1.46% 19:27 07/12 EDT
OPEN
5.00
PREV CLOSE
4.910
HIGH
5.04
LOW
4.730
VOLUME
552.95K
TURNOVER
0
52 WEEK HIGH
7.00
52 WEEK LOW
2.570
MARKET CAP
262.71M
P/E (TTM)
-5.1448
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRMD last week (0701-0705)?
Weekly Report · 6d ago
CORMEDIX INC. ANNOUNCES OUTPATIENT AVAILABILITY OF DEFENCATH
Reuters · 07/03 12:03
Weekly Report: what happened at CRMD last week (0624-0628)?
Weekly Report · 07/01 10:42
Weekly Report: what happened at CRMD last week (0617-0621)?
Weekly Report · 06/24 10:47
Truist Financial Sticks to Its Buy Rating for Cormedix (CRMD)
TipRanks · 06/20 11:25
CorMedix Price Target Maintained With a $10.00/Share by Needham
Dow Jones · 06/19 09:55
Needham Reiterates Buy on Cormedix, Maintains $10 Price Target
Benzinga · 06/19 09:45
Expanding Markets and Anticipated Profitability: A Buy Rating for Cormedix on DefenCath’s Growth Prospects
TipRanks · 06/18 18:25
More
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

Webull offers CorMedix Inc stock information, including NASDAQ: CRMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRMD stock methods without spending real money on the virtual paper trading platform.